ENLV

Enlivex Ltd.
CAPPED RATING

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Enlivex Ltd. (ENLV) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B+
Factor Score 3.8 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
D-
Factor Score 1.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -0.6
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -40.3%
Price Return 12M -92.0%
Catalyst Signal 0.00
Market Cap $1.8M
TTM Revenue N/A
Price / Sales N/A
ROE 162.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B+ (3.8) D+ (1.8) C- (2.1) D- (1.0) C+ (2.6) C (2.3)
2026-11-04 B+ (3.8) C- (1.9) C- (2.0) D (1.2) C+ (2.7) C (2.3)
2026-10-28 B+ (3.8) C- (1.9) C (2.2) F (0.3) C+ (2.7) C- (2.1)
2026-10-21 B+ (3.8) D+ (1.8) C (2.2) F (0.3) C+ (2.6) C- (2.1)
2026-10-14 B+ (3.7) D+ (1.8) C (2.2) F (0.3) C+ (2.6) C- (2.1)
Page 1 of 4